Completed PHASE4 INTERVENTIONAL NCT00216515

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

A Prospective, Open-labeled, Multicenter Study of Galantamine on the Attention and Frontal Function of the Patients With Dementia of Alzheimer Type

Sponsor: Janssen Korea, Ltd., Korea

Conditions Alzheimer Disease

Interventions galantamine hydrobromide

Updated 5 times since 2017 Last updated: Jan 20, 2011 Started: Mar 31, 2004 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00216515, this PHASE4 trial focuses on Alzheimer Disease and remains completed. Sponsored by Janssen Korea, Ltd., Korea, it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Korea, Ltd., Korea

Data source: Janssen Korea, Ltd., Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.